Plenary Sessions

Sunday, July 30

CRISPR Biology, Technology & Ethics: The Future of Genome Engineering Jennifer Doudna
Jennifer Doudna, PhD
Professor of Chemistry and of Molecular and Cell Biology
Department of Chemistry and Chemical Engineering
University of California, Berkeley

Facile genome manipulation using precision DNA and RNA recognition is transforming biology. This presentation will describe how the bacterial CRISPR adaptive immune system continues to inspire development of powerful genome engineering tools, enabling advances in both fundamental biology and applications to the mammalian brain.





Monday, July 31

TKWOncofertility: From Bench to Bedside to Babies
Teresa K. Woodruff, PhD, DSc
Thomas J. Watkins Professor of Obstetrics and Gynecology
Vice Chair of Research, Department of Obstetrics and Gynecology
Director, Oncofertility Consortium
Professor of Molecular Biosciences
Feinberg School of Medicine, Northwestern University

Life preserving cancer treatments can threaten fertility. More than 1.4 million people are diagnosed in the U.S. with cancer annually; 10% of these individuals are in their reproductive years (up to 45 years old). As the survival rate for adolescents and children continues to rise, late effects of treatment are taking on new urgency for survivors of this disease. Oncofertility is a new term that describes the effort to preserve positioning elementfertility for young people with cancer and includes basic reproductive biology, clinical science, ethics, law, economics, pediatric surgery, and education sciences.



Tuesday, August 1

Jay ShendureBeyond Sequencing: New Frontiers in Genomics
Jay Shendure, MD, PhD
Professor of Genome Sciences
University of Washington

Over the past decade, massively parallel or next-generation DNA sequencing has emerged as a broadly enabling 21st century "microscope" for the measurement of diverse biological phenomena. In the clinic, the utility of sequence data is being intensively evaluated in diverse positioning elementcontexts, including reproductive medicine, oncology, and infectious disease, and sequencing is increasingly being used in unanticipated ways that reach beyond conventional human genetics. This presentation will focus on efforts to develop new applications for DNA sequencing in clinical medicine, including for non-invasive diagnostics and for decomposing complex cell populations.



Wednesday, August 2

FraserAntibiotic Resistance: A Public Health Crisis
Victoria Fraser, MD
Adolphus Busch Professor of Medicine and Chairman
Department of Medicine
Washington University School of Medicine

The major challenges in antimicrobial resistance nationwide as well as the evolving diagnostic tools and strategies for prevention and control of antimicrobial resistance in hospitals will be discussed. In addition, the important role of the clinical pathology laboratory in infection prevention and antimicrobial stewardship will be reviewed.







Thursday, August 3

photo of mclellan Modern, Effective Care for Substance Use Disorders: Findings from the 2016 Surgeon General’s Facing Addiction Report
A. Thomas McLellan, PhD
Chairman
Treatment Research Institute

Over 22 million Americans meet medical diagnostic criteria for addiction to alcohol and/or other drugs. Sadly, overall prevalence rates and costs have not declined over the decades leading to the view that substance misuse and addiction may simply be an intractable part of our culture. But there is one exception—cigarette use. The prevalence, health harms, and costs associated with cigarette use have been dramatically reduced over the past four decades as a direct result of broadly applied science-based public health policies and clinical practices. Using the three decades of research overviewed and synthesized in the recent Surgeon General’s Report entitled “Facing Addiction in the United States,” this presentation argues that a similar science-based strategy would be possible, practical, and cost effective to implement, with expectable public benefits comparable to those seen with cigarettes.